• Home
• Mailbox
• Boards
• Favorites
• Whats Hot!
• Login - Join Now!

Search Search Type Board Post Member

Profile

About Latest Posts Latest Blog Posts Boards Posted On Boards Moderating

D E's Profile

Avatar:

Membership:

Premium

Person Marks:

4

Total Posts:

14

Total Blog Posts:

0

Total Compensated Posts:

0

Moderating:

0

Alias Born

06/29/2012 12:28:20 PM

Personal info

Recent Articles

• STL Launches Advanced Data Centre Solutions for AI Demand
• Constellium's Innovations Shine at the Paris Air Show 2025
• Roche Moves Forward with Prasinezumab for Early-Stage Parkinson's
• Rolf Gobet Joins WISeKey's Advisory Committee on Strategy
• PingPong Introduces InvestXB: A Game Changer for Investors
• Exploring the Rise of U.S. Latinos and Their Brand Expectations
• Revolutionizing Aircraft Performance with GTF Hot Section Plus
• Queclink Strengthens European Operations with New Office
• Tencent Cloud Enhances AI Capabilities for European Enterprises
• Queclink Strengthens European Market with New Office Venture
• Jingle Pay Partners with Western Union for Global Transfers
• Ursa Major's New Hypersonic Engine Contract Boosts National Defense
• PayPal's Innovative Storefront Ads: Revolutionizing E-Commerce Reach
• Innovative AI Multimodal Learning Platform Set to Transform Learning
• Empowering Africa's Children Through Quality Education Initiatives
• Exploring the Evolution of Urban-Rural Transport in China
• DDB Capital Enhances Investment Focus in North Alabama Housing
• Anticipation Grows for the 2nd China-Central Asia Summit
• Revitalizing Heritage: A Journey Through Dunhuang's Culture
• Abbisko Therapeutics Advances Irpagratinib Study for HCC Treatment
• China to Host 6th Multinationals Summit, Encouraging Investment
• SDP Japan Secures $31 Million to Transform Surgical Care
• Tokyo Gas Triumphs in Cloud Native Case Study Competition
• Significant Subgroup Analysis of Cadonilimab in Cervical Cancer
• Stavian Chemical Achieves Major Milestone in Global Rankings
• ArkBio's Azstarys Approved for ADHD Treatment Review in China
• Strategic Thinking in China's Development Plans and Governance
• Industrial Lubricants: Insights and Future Market Trends Ahead
• Innovent's Mazdutide Advances with First Patient Dosed in Trial
• Innovative Treatment Strategies Highlighted at EHA 2025 Conference
• Celltrion Gains FDA Nod for New STEQEYMA® Pediatric Formulation
• Innovative Drug Screening Services Introduced by Samsung Biologics
• Transforming Transit: $4 Billion to Electrify Buses in Canada
• Abaxx Technologies Launches Innovative Gold Futures Trading
• 2025 Meijer LPGA Classic Makes Impact with $1.5 Million
• Bombardier's Global 7500 Establishes New Speed Benchmark
• IDEX Biometrics ASA Announces Significant Share Issuance to Personnel
• Investors Urged to Join Class Action Against West Pharmaceutical Services
• Honoring Leonard A. Lauder: A Legacy in Alzheimer's Research
• Elevate Your Earnings with PFMCrypto's Exciting XRP Giveaway
• AIXA Miner Celebrates Groundbreaking Milestone in Green Mining
• Oma Savings Bank Plc Revises Profit Outlook: Important Update
• Transformative Leadership Change at Renault Group Announced
• Deadline for Fortrea Holdings Inc. Investors in Lawsuit Ahead
• Dupixent® Triumphs in Phase 4 Trial Against Xolair® for CRSwNP
• Dupixent vs. Xolair: Breakthrough Findings in Asthma Treatment
• Faruqi & Faruqi Investigates Ibotta's Legal Claims for Investors
• Red Cat Holdings Faces Legal Challenges Amid Investor Concerns
• Investor Alert: Key Updates on Iovance Biotherapeutics Lawsuit
• Investors Alert: Faruqi & Faruqi Advocate for Open Lending Claims